MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.00
-0.97
-1.86%
Opening 10:49 02/25 EST
OPEN
52.53
PREV CLOSE
51.96
HIGH
52.97
LOW
50.38
VOLUME
211.32K
TURNOVER
--
52 WEEK HIGH
74.00
52 WEEK LOW
33.55
MARKET CAP
2.40B
P/E (TTM)
52.51
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRSP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRSP stock price target is 75.96 with a high estimate of 104.00 and a low estimate of 28.00.

EPS

CRSP News

More
  • Precision BioSciences: Consider Taking Up A Small Position
  • Seeking Alpha - Article · 23h ago
  • CRISPR Should Continue The Bullish Pace From 2019
  • Seeking Alpha - Article · 1d ago
  • Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
  • MotleyFool.com · 2d ago
  • Better Buy: CRISPR Therapeutics vs. Intellia
  • MotleyFool.com · 3d ago

Industry

Biotechnology & Medical Research
-1.63%
Pharmaceuticals & Medical Research
-0.92%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CRSP

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
More

Webull offers kinds of Crispr Therapeutics AG stock information, including NASDAQ:CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions.